BRPI0409230A - formas de dosagem compreendendo ag013736 - Google Patents

formas de dosagem compreendendo ag013736

Info

Publication number
BRPI0409230A
BRPI0409230A BRPI0409230-9A BRPI0409230A BRPI0409230A BR PI0409230 A BRPI0409230 A BR PI0409230A BR PI0409230 A BRPI0409230 A BR PI0409230A BR PI0409230 A BRPI0409230 A BR PI0409230A
Authority
BR
Brazil
Prior art keywords
dosage forms
prodrugs
solvates
mammal
cancer
Prior art date
Application number
BRPI0409230-9A
Other languages
English (en)
Inventor
James Lawrence Freddo
Dana Hu-Lowe
Yazdi Kersi Pithavala
Heidi Marie Steinfeldt
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0409230A publication Critical patent/BRPI0409230A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"FORMAS DE DOSAGEM COMPREENDENDO AG013736". A invenção refere-se a formas de dosagem de um composto de fórmula (1) ou seus sais, solvatos ou pró-fármacos farmaceuticamente aceitáveis. Adicionalmente, a invenção proporciona métodos de tratamento do crescimento celular anormal, tal como câncer, pela administração de formas de dosagem a um mamífero.
BRPI0409230-9A 2003-04-03 2004-03-17 formas de dosagem compreendendo ag013736 BRPI0409230A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46069503P 2003-04-03 2003-04-03
US49177103P 2003-07-31 2003-07-31
PCT/IB2004/000867 WO2004087152A1 (en) 2003-04-03 2004-03-17 Dosage forms comprising ag013736

Publications (1)

Publication Number Publication Date
BRPI0409230A true BRPI0409230A (pt) 2006-03-28

Family

ID=33135143

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409230-9A BRPI0409230A (pt) 2003-04-03 2004-03-17 formas de dosagem compreendendo ag013736

Country Status (16)

Country Link
US (1) US20040224988A1 (pt)
EP (1) EP1613320A1 (pt)
JP (1) JP2006522087A (pt)
KR (1) KR20050119671A (pt)
AR (1) AR043822A1 (pt)
AU (1) AU2004226586B2 (pt)
BR (1) BRPI0409230A (pt)
CA (1) CA2520932A1 (pt)
MX (1) MXPA05009303A (pt)
NL (1) NL1025873C2 (pt)
NO (1) NO20055143L (pt)
PA (1) PA8599701A1 (pt)
RU (2) RU2341263C2 (pt)
TW (1) TW200423933A (pt)
UY (1) UY28255A1 (pt)
WO (1) WO2004087152A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
CN101052633A (zh) * 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
KR20070058690A (ko) * 2004-11-02 2007-06-08 화이자 인코포레이티드 인다졸 화합물의 제조방법
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP4249063A3 (en) 2007-04-05 2024-03-13 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
CN101801413A (zh) * 2007-07-12 2010-08-11 托勒克斯股份有限公司 采用gitr结合分子的联合疗法
KR20110036101A (ko) 2008-06-30 2011-04-06 안지오블라스트 시스템스 인코퍼레이티드 조합된 치료를 사용한 안과질환 및 과도한 혈관신생의 치료
TW201328725A (zh) 2011-09-30 2013-07-16 Pfizer Ｎ－甲基－２－［３－（（ｅ）－２－吡啶－２－基－乙烯基）－１ｈ－吲唑－６－基硫烷基］苯甲醯胺之藥學組成物
CA2855211A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
SI3102605T1 (sl) 2014-02-04 2019-04-30 Pfizer Inc. Kombinacija PD-1 antagonista in VEGFR inhibitorja za zdravljenje raka
JP6414727B2 (ja) * 2014-04-01 2018-10-31 公益財団法人ヒューマンサイエンス振興財団 関節疾患の治療予防剤
CN104013589A (zh) * 2014-05-07 2014-09-03 万特制药(海南)有限公司 一种阿西替尼口腔崩解片及其制备方法
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
BR112017018234A2 (pt) 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
CA3012718A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
WO2018065938A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
AU2023227442A1 (en) 2022-03-03 2024-09-12 Pfizer Inc. Multispecific antibodies and uses thereof
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI941572L (fi) * 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993016185A2 (en) * 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5339184A (en) * 1992-06-15 1994-08-16 Gte Laboratories Incorporated Fiber optic antenna remoting for multi-sector cell sites
US5459607A (en) * 1993-04-19 1995-10-17 C-Cor/Comlux, Inc. Synchronous optical digital transmission system and method
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP3053222B2 (ja) * 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JP3588984B2 (ja) * 1997-08-20 2004-11-17 Ｋｄｄｉ株式会社 光パワー計測システム並びにそのための端局及び中継器
GB2332603B (en) * 1997-12-22 2000-07-19 Lsi Logic Corp Improvements relating to multidirectional communication systems
US6529303B1 (en) * 1998-03-05 2003-03-04 Kestrel Solutions, Inc. Optical communications networks utilizing frequency division multiplexing
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US6643470B1 (en) * 1999-10-01 2003-11-04 Matsushita Electric Industrial Co., Ltd. FM signal converter, FM signal optical transmitter and FM signal optical receiver

Also Published As

Publication number Publication date
KR20050119671A (ko) 2005-12-21
NL1025873C2 (nl) 2006-02-14
NO20055143L (no) 2006-01-03
WO2004087152A1 (en) 2004-10-14
PA8599701A1 (es) 2004-11-26
JP2006522087A (ja) 2006-09-28
AR043822A1 (es) 2005-08-17
NO20055143D0 (no) 2005-11-02
TW200423933A (en) 2004-11-16
UY28255A1 (es) 2004-11-30
AU2004226586B2 (en) 2008-12-11
RU2005128791A (ru) 2006-05-10
CA2520932A1 (en) 2004-10-14
EP1613320A1 (en) 2006-01-11
RU2008122358A (ru) 2009-12-10
MXPA05009303A (es) 2005-10-05
RU2341263C2 (ru) 2008-12-20
US20040224988A1 (en) 2004-11-11
AU2004226586A1 (en) 2004-10-14
NL1025873A1 (nl) 2004-10-05

Similar Documents

Publication Publication Date Title
CR20240147A (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
MXPA05009303A (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr.
ECSP055867A (es) Derivados de pirrolopirimidina
BR0313942A (pt) Derivados de benzimidazol úteis como agentes antiproliferativos
CR20210602A (es) Compuestos de pirrolidina
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
NO20062704L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
NO20073743L (no) Forbindelser med Kv4 ionekanal aktivitet
IL157254A0 (en) N-substituted nonaryl-heterocyclic nmda/mr2b antagonists
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
GB0112348D0 (en) Compounds
EA201070597A1 (ru) Антибактериальные аналоги аминогликозида
GEP20125589B (en) TRIAZINE COMPOUNDS AS P13 KINASE AND mTOR INHIBITORS
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
MX356203B (es) Compuestos tetraciclicos sustituidos con heterociclo y metodos de uso de los mismos para el tratamiento de enfermedades viricas.
MX2007013624A (es) Inhibidores de proteina cinasa.
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
UY27980A1 (es) Indoles 2,7-sustituidos
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.